Arecor Therapeutics (LSE:AREC) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:AREC Arecor Therapeutics PLC LSE:AREC
37 GF Score
Price £0.61
GF Value £0.44
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LSE:AREC
37GF Score
Arecor Therapeutics PLC LSE:AREC
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arecor Therapeutics (LSE:AREC) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of £0.61 is trading 38.6% above its estimated GF Value™ of £0.44. GuruFocus considers Arecor Therapeutics to be Significantly Overvalued.

Key valuation signals for LSE:AREC:

  • Short Ratio:
  • GF Value™: £0.44 vs. price of £0.61 (38.6% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the LSE:AREC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arecor Therapeutics Business Description

Other Exchanges 6UI:Germany
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score

Get the complete analysis for LSE:AREC

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.61
Price
£0.44
GF Value